A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

Phase 1

• Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancer
• Interventions: Drug: WX-0593 Tablets

• Registration Number: NCT03389815
• Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Brief Summary

The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593 alone in the treatment of advanced cancer.

Detailed Description

The first part is a single-arm, phase 1, open label, dose-escalation design in patients with anaplastic lymphoma kinase（ALK）/receptor tyrosine kinase（ROS1） Positive ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in anaplastic lymphoma kinase(ALK) expression.

Study Timeline

• Study Start: 2017-09-14
• Status Verified: 2017-12
• Study First Submitted: 2017-12-06
• Study First Submitted QC: 2017-12-26
• Last Update Submitted: 2017-12-26
• Study First Posted: 2018-01-04
• Last Update Posted: 2018-01-04
• Primary Completion: 2020-06
• Study Completion: 2020-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. 18 to 70 years, inclusive.

2. Female or male

3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

4. Life expectancy of at least 12 weeks.

5. At least one measurable lesion (according to RECIST v1.1)

6. Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy with ALK/ROS1+ (For the expansion phase, patients must have NSCLC with ALK+ ):

   • Patients with advanced tumor (eg. NSCLC, lymphoma, inflammatory myofibroblastic tumor) who failed in standard treatment (eg. resistant of ALK inhibitors or chemotherapy)
   • Patients with advanced NSCLC who cannot accept chemotherapy or intolerance with chemotherapy.
   • Advanced NSCLC patients who could not afford ALK inhibitor treatment.

7. Patients with treated or untreated asymptomatic Central Nervous System（CNS） metastases may be allowed to enroll.

8. Patients must have normal function as defined: ANC≥1.5*10^9/L PLT≥100*10^9/L， Total Bilirubin （TBIL）≤1.5*Upper Limit of Normal（ULN） ( Gilbert's Syndrome TBIL ≤3.0*ULN and DBIL≤1.5*ULN )，Alanine Transaminase （ALT）and Aspartate Aminotransferase（AST）≤2.5*ULN. For liver metastasis patients, ALT and AST≤5*ULN, Cr≤1.5*ULN, LVEF≥50%.

9. Any surgery or radiation (expect for palliative radiation) must have been completed at least 4 weeks prior to first dosing. Palliative radiation must have been completed at least 48 hours prior to first dosing.

10. All related adverse events from previous anti-cancer therapies must have recovered to ≤ Grade 1 (except for alopecia).

11. Patients must be able to understand and volunteer to sign the informed consent.

Exclusion Criteria

1. Clinically significant cardiovascular disease within 3 months prior to first dosing.
2. Ongoing cardiac dysrhythmias, or any grade of uncontrolled atrial fibrillation, or prolonged QT interval (QTc > 480 ms).
3. Patients need medications that may prolong QT interval or induce torsades de pointes within 14 days prior to the first dosing or during the study.
4. Peripheral neuropathy ≥ Grade 3 according to CTCAE 4.03.
5. Patients who received continuous use of steroids for more than 30 days, or who need long-term use of steroid hormones or other immunosuppressive agents.
6. History of extensive disseminated/bilateral pulmonary interstitial fibrosis, interstitial fibrosis or interstitial lung disease of Grade 3/4 .
7. Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of WX-0593.
8. Patients who are receiving warfarin sodium (Coumadin) or any other coumadin-derived anticoagulants，and patients with coagulation disturbance and bleeding tendency.
9. Patient has received other investigational drug within 1 month.
10. Patients with acute or chronic infectious medical conditions, including active hepatitis (Hepatitis A、 Hepatitis B、 Hepatitis C ) or HIV infection.
11. Patients who received prior anti-cancer therapy within 2 weeks (t1/2 ≤ 3 days) or within 4 weeks (3 days < t1/2）. Patients previously treated with crizotinib could start WX-0593 dosing after 1 week from the last dosing.
12. Patients who could not discontinue therapy with potent CYP3A4 inhibitors or inducers within 1 week prior first dosing, or patients who need therapy with CYP3A4 inhibitors or inducers during the study.
13. Patients received medications known to be metabolized by CYP3A4 and with narrow therapeutic indices, who could not discontinue within 1 week prior to the start of WX-0593 administration. Patients who need therapy with those medications during the study.
14. Females who are pregnant or breastfeeding.
15. Patients with childbearing potential must agree to use adequate contraception for the duration of treatment and for 6 months after the study.
16. Drug abusers and alcoholics.
17. History of definite nerves or psychosis diseases including epilepsy or dementia.
18. History of other malignancy.
19. Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
WX-0593 Tablets	WX-0593 Tablets	The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose（MTD）	28 days	The MTD is determined by the number of the participants in cohort who suffer a dose-limiting toxicity (DLT). The MTD is defined as the former dose at which more than one third of the participants develop a DLT. If no DLTs are observed, the MTD is not reached.

Secondary Outcome Measures

Name	Time	Method
Tmax of WX-0593	28 days	Pharmacokinetics of WX-0593 by assessment of time to Cmax
Cmax of WX-0593	28 days	Pharmacokinetics of WX-0593 by assessment of maximum plasma WX-0593 concentration.
Cmin of WX-0593	28 days	Pharmacokinetics of WX-0593 by assessment of minimum plasma WX-0593 concentration.
AUC of WX-0593	28 days	Pharmacokinetics of WX-0593 by assessment of area under the plasma concentration time curve from zero to infinity
tl/2 of WX-0593	28 days	Pharmacokinetics of WX-0593 by assessment of the terminal half-life
Cssmin of WX-0593	28 days	Cmin of WX-0593 at steady state
AUCss of WX-0593	28 days	area under the curve of WX-0593 at steady state
DF of WX-0593	28 days	Pharmacokinetics of WX-0593 by assessment of degree of fluctuation
Cssmax of WX-0593	28 days	Cmax of WX-0593 at steady state
Css-av of WX-0593	28 days	Mean plasma concentration of WX-0593 at steady state
CLs of WX-0593	28 days	total plasma,serum or blood clearance of WX-0593 after administration
Disease Control Rate (DCR)	From fist administration of WX-0593 to 28 days after last medication.	DCR is the percentage of patients with best response of CR, PR or Stable Disease (SD).; SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter.
Vz of WX-0593	28 days	volume of distribution during terminal phase after WX-0593 administration
Progression-free survival (PFS)	From fist administration of WX-0593 to 28 days after last medication.	PFS defined as the time from baseline to first observed disease progression or death from any cause.
Duration of Response (DOR) and so on	From fist administration of WX-0593 to 28 days after last medication.	The DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date on which progressive disease (PD) is first noted or date of death.
Objective Response Rate (ORR)	From fist administration of WX-0593 to 28 days after last medication.	Primary efficacy endpoint is a change in the proportion of subjects showing overall objective response rate (ORR) from baseline to final tumor assessment point after treatment. As Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, the percentage of subjects indicating PR (partial response) and CR (complete response) will be calculated.; According to RECIST 1.1 criteria, complete response (CR) - the disappearance of all target lesions and partial response ( PR ) - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.

Trial Locations

Locations (1)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, Beijing, China